Towa Pharmaceutical is moving to bring more manufacturing inside the group, after approving a deal to buy all shares in Tanabe Pharma Factory from Tanabe Pharma and to take over 35 manufacturing and marketing approvals covering 17 active ingredients. The company said the combination should strengthen its ability to supply high-quality drugs on a sustained basis and secure more domestic production capacity.
A factory with earnings attached
This is not just a transfer of approvals. Tanabe Pharma Factory, based in Osaka and wholly owned by Tanabe Pharma, makes, sells and imports medicines. In the year ended March 2026 it reported net assets of ¥31.66bn, sales of ¥15.78bn and operating profit of ¥1.14bn. Towa said the business already has manufacturing and quality-control systems built to global standards, which is part of the attraction.
| Item | Detail |
|---|---|
| Stake to be acquired | 22,602 shares, 100% of Tanabe Pharma Factory |
| Approval transfer | 17 active ingredients, 35 products (planned) |
| Target sales, year ended March 2026 | ¥15.78bn |
| Target operating profit, year ended March 2026 | ¥1.14bn |
| Planned share transfer | Late November 2026, subject to competition-law clearance |
| Planned approval transfer | From April 2027 onward, subject to competition-law clearance |
| Factory capacity target | 4bn to 5bn tablets by 2036 |
| Group capacity target | 24bn tablets by 2030, more than 30bn by 2036 |
More products, more integration
Towa said inheriting the approvals should expand its product portfolio, allow integration with overlapping items already sold by the group and improve production efficiency. It also cast the deal as a way to inherit manufacturing technology and know-how built up by a long-established originator-drug company. The appendix lists 35 products across 17 ingredients, including cardiovascular, psychiatric, antihistamine and sleep-related medicines.
The catch is timing, and the payoff is capacity
The timetable is staggered. Towa plans to complete the share transfer in late November 2026, covering 22,602 shares, and start the approval transfers from April 2027 onward. Both steps are subject to competition-law clearance.
The price for the shares and for the approvals was not disclosed, under an agreement between the two sides. Towa did say it expects negative goodwill to arise, but the amount and any effect on its forecast for the year ending March 2027 will only be disclosed once details are fixed.
The longer-term target is straightforwardly industrial. Towa said it plans capital spending to raise Tanabe Pharma Factory's production capacity to 4bn to 5bn tablets by 2036. Combined with larger equipment, better efficiency at Towa's existing three plants and outsourced volumes through partnerships, the group is targeting capacity of 24bn tablets by 2030 and more than 30bn by 2036. In other words, the deal is less about buying a catalogue and more about buying room to manufacture it.